Sunday, July 26, 2009

Fwd: CENTRAL GOVERNMENT EMPLOYEES NEWS



---------- Forwarded message ----------
From: CENTRAL GOVERNMENT EMPLOYEES NEWS <ushanandhinite@gmail.com>
Date: 2009/7/25
Subject: CENTRAL GOVERNMENT EMPLOYEES NEWS
To: gomarwah@gmail.com


CENTRAL GOVERNMENT EMPLOYEES NEWS


Enhancement of Child Adoption Leave from 135 days to 180 days and extension of the facility of Paternity Leave to adoptive fathers

Posted: 24 Jul 2009 07:31 PM PDT



No. 13018/1/2009-Estt.(L)

GOVERNMENT OF INDIA

Ministry of Personnel, Public Grievances & Pensions

(Department of Pension & Pensioners'Welfare)

Lok Nayak Bhawan,New Delhi-110003
dated the 22nd July, 2009

OFFICE MEMORANDUM


Sub: Enhancement of Child Adoption Leave from 135 days to 180 days and extension of the facility of Paternity Leave to adoptive fathers.



The undersigned is directed to refer to this Department's O.M. No.13018/4/2004-Estt.(L) dated 31st March, 2006 regarding grant of Child Adoption Leave for 135 days to female Government servant on adoption of a child upto the age of one year, on the lines of maternity leave admissible to natural mothers. After implementation of the Sixth Central Pay Commission recommendations, the period of maternity leave was enhanced from 135 days to 180 days. Subsequently, this Department has received representations requesting for enhancement of the period of Child Adoption Leave from 135 days to 180 days in line with the maternity leave. The matter has been examined in this Department and it has been decided to enhance the period of Child Adoption Leave from 135 days to 180 days.


2. A female Government servant in whose case the period of 135 days of Child Adoption Leave has not expired on the date of issue of these orders shall also be eligible for Child Adoption Leave of 180 days.


3. It has also been decided that a male Government servant (including an apprentice) with less than two surviving children, on valid adoption of a child below the age of one year, may be sanctioned Paternity Leave for a period of 15 days within a period of six months from the date of valid adoption.


4. These orders shall take effect from the date of issue.


5. In so far as persons serving in the Indian Audit and Accounts Department are conceded, these orders issue in consultation with the Comptroller and Auditor General of India.

this is a test message
You are subscribed to email updates from CENTRAL GOVERNMENT EMPLOYEES NEWS
To stop receiving these emails, you may unsubscribe now.
Email delivery powered by Google
Inbox too full? Add to Google
Google Inc., 20 West Kinzie, Chicago IL USA 60610



--
Dr Marwah

Monday, July 20, 2009

Vitamer EA is benfotiamine a dietary supplement


https://www.benfotiamine.net/ShoppingCart.aspx?Category=0

Vitamer EA is benfotiamine a dietary supplement 
 

1. WHAT IS BENFOTIAMINE?

2. IS BENFOTIAMINE SAFE?

3. HAVE THERE BEEN RECENT CLINICAL TRIALS USING BENFOTIAMINE?

4. HOW ABOUT INTERACTIONS WITH OTHER MEDICATIONS?

5. WHAT TYPE OF CONDITIONS MAY RESPOND WELL TO BENFOTIAMINE?

6. HOW MUCH BENFOTIAMINE SHOULD I USE DAILY?

7. WHAT IS THE FDA POSITION ON BENFOTIAMINE?

8. WHY HAVEN'T I HEARD OF BENFOTIAMINE BEFORE?

9. WHAT DOES "PHARMACEUTICAL GRADE" MEAN?

10. HAVE YOU RECEIVED ANY TESTIMONIALS?

11. WHERE CAN I BUY BENFOTIAMINE? 

1.  WHAT IS BENFOTIAMINE?

Benfotiamine is a lipid-soluble form of thiamine (vitamin B-1).  It is perhaps the most effective of the allithiamine group of naturally occurring, thiamine-derived compounds, found in trace quantities in roasted crushed garlic and other vegetables from the Allium genus (such as onions, shallots, and leeks).  The best description of benfotiamine I have found was assembled by AOR, a Canadian nutriceutical company:  Abstracts & Summary Description of Benfotiamine.  If you are interested in the benfotiamine molecule, you may view it here:  Benfotiamine Molecule You may also view the original U.S. patent for benfotiamine here:  Adobe Version of Benfotiamine Patent.

Back To Top 

2.  IS BENFOTIAMINE SAFE?

Though benfotiamine is lipid-soluble, it metabolizes quickly, producing high levels of thiamine pyrophosphate (TPP, the active form of thiamine), which then continues to metabolize in the body as usual.  Benfotiamine itself does not accumulate in the body.  The original patent filed in the United States on benfotiamine, Adobe Version of Benfotiamine Patent, included data from LD-50 tests on lab mice (Table III) indicating that benfotiamine is significantly less toxic than common vitamin B-1 (typically, thiamine hydrochloride).  Thiamine hydrochloride has been the subject of much research.  To quote from the European Commission Health and Consumer Protection Directorate General study on the tolerable upper intake level of vitamin B-1, paragraph 3. Hazard Identification:

"3.1. Evidence of adverse effects in humans. Orally ingested vitamin B1 has a long history of use as an oral supplement without reported adverse effects. Due to its therapeutic action in some frequently observed clinical syndromes, thiamine hydrochloride has been advised and used over a long period of time. There are no reports of adverse effects of oral thiamine, even at dosages of several hundred milligrams a day (SCOGS, 1978; DHEW, 1979; Marks, 1989)."

The entire EC study is available at:  Tolerability of Thiamine (Vitamin B-1).  Again, vitamin-B-1 has proven safe after decades of public use and benfotiamine has been found to be significantly more tolerable than common vitamin B-1.  Also, there are no known negative interactions between benfotiamine and other supplements or medications.  However, there is information published by Ohio State University in 1996 and by the European Journal of Biochemistry in 2001 indicating thiamine supplementation should be carefully considered in patients undergoing therapy for tumorous forms of CANCER.  These articles address thiamine in general (not specifically benfotiamine) but I find them relevant since benfotiamine is essentially a very effective form of thiamine.  You may access that information here:  OSU Article, EJB Abstract.

Otherwise, I believe there is minimal to nil downside in trying benfotiamine and the individual results have the potential to be quite significant.  Still, it is wise and prudent to consult your health care provider before beginning a benfotiamine regimen.  Also, if you have a known sensitivity to thiamine, you should check with your health care provider before using benfotiamine.

Back To Top 

3.  HAVE THERE BEEN RECENT CLINICAL TRIALS USING BENFOTIAMINE?

Yes, in the past couple of years interest in this compound has grown significantly.  You may link to some of the recent clinical trial abstracts here: Clinical Trials.

Back To Top 

4.  HOW ABOUT INTERACTIONS WITH OTHER MEDICATIONS?

Benfotiamine has no known negative interactions with any medications.  In fact, the use of some medications may cause a thiamine deficiency which benfotiamine would likely correct:  Interactions.

Back To Top 

5.  WHAT TYPE OF CONDITIONS MAY RESPOND WELL TO BENFOTIAMINE?

While the recent clinical trials have concentrated on conditions such as neuropathy, retinopathy and nephropathy, there is an expectation among those studying this compound that its beneficial effects may be far more wide-ranging, to include:  sciatica, vascular health, general nerve health, improved blood pressure, general cellular protection, anti-aging, fibromyalgia, prevention of lactic acidosis, and treatment for Alzheimer's disease.  A most informative link on this topic is:  Abstracts & Summary Description of Benfotiamine.

Benfotiamine is not just for diabetics.  Any condition that is the result of a thiamine deficiency will likely respond quite well to benfotiamine.  Of course, any bodily function that is improved by a therapeutic level of thiamine would most likely be enhanced by benfotiamine, since benfotiamine is perhaps the most effective form of thiamine.  Some interesting facts regarding thiamine can be found at this link:  Thiamine Facts.   More on thiamine can be found here:  More Thiamine Facts.

Back To Top 

6.  HOW MUCH BENFOTIAMINE SHOULD I USE DAILY?

Though the body cannot use more than about 10mg. of common, water-soluble vitamin B-1 per day, benfotiamine is lipid-soluble and can safely be used at much higher levels than common vitamin B-1.

Most people get excellent results in 14-21 days time using two 150mg. capsules twice per day (two in the morning and two in the evening). Benfotiamine need not be taken with meals. Some people get better results increasing the dosage to 900mg. or 1200mg. per day after the first two weeks. The point here is that benfotiamine is safe at any reasonable daily usage level. An individual should merely find the level that produces the maximum beneficial effect without reaching a point of diminishing return beyond which the excess amount is wasted.

Dr. Brownlee participated in a clinical trial using 600mg./day:  Clinical Trial Using 600mg. Daily. As for me, I noted dramatic results after increasing daily usage to 600mg.  My neuropathy symptoms ceased progression and began to reverse and I experienced a complete cessation of sciatica episodes.  Also, my average blood pressure dropped from a persistent 145/90 to 120/80, without the use of other blood pressure medications.  I now take two capsules in the morning and two in the evening, everyday. 

Back To Top 

7. WHAT IS THE FDA POSITION ON BENFOTIAMINE?

At first I was curious as to whether benfotiamine is considered a drug or a supplement.  I have established to my satisfaction (and based on the expert opinion of others in the industry) that benfotiamine, a synthetic derivative of vitamin B-1, is a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994.  During 2003 I have successfully imported to the U.S. both bottled tablets as well as bulk benfotiamine, with full disclosure and full FDA and U.S. Customs review and approval at the respective U.S. ports of entry.  Let me emphasize that.  The FDA did a hands-on review and inspection of my imported benfotiamine, with full disclosure as to contents by both name and chemical formula, and approved all items for import.  Benfotiamine may be imported under Tariff Number:  2936.22.00.00, (thiamine and its derivatives).   

For those curious as to the current FDA stance on dietary supplements, I offer the following quote from their website:

"Under DSHEA, a firm is responsible for determining that the dietary supplements it manufactures or distributes are safe and that any representations or claims made about them are substantiated by adequate evidence to show that they are not false or misleading. This means that dietary supplements do not need approval from FDA before they are marketed."  See:  http://www.cfsan.fda.gov/~dms/ds-oview.html.   As to the safety of benfotiamine, please see the data provided above in this document. 

Back To Top 

8. WHY HAVEN'T I HEARD OF BENFOTIAMINE BEFORE?

Though attempts were made by the Japanese pharmaceutical manufacturer Sankyo to market benfotiamine in the U.S. decades ago, there was little interest until the recent article published in the U.S. by Dr. Brownlee.  Since that time, interest in benfotiamine has increased dramatically.  I have heard some speculation that since the patent on benfotiamine expired years ago, no large company is interested in investing in its promotion.  I personally remain mystified as to why this very beneficial compound has languished in obscurity in this country until now.

Back To Top 

9. WHAT DOES "PHARMACEUTICAL GRADE" MEAN?

"Pharmaceutical grade" means that the product has been manufactured under GMP conditions and is safe, pure and effective.  Under GMP (Good Manufacturing Practices) every step of the process is documented by using established SOPs (Standard Operating Procedures).  This includes training, equipment, raw materials, facilities, and final release criteria.  Everything can be traced back to the date, time, person, lot number, and piece of equipment used.

Back To Top 

10.  HAVE YOU RECEIVED ANY TESTIMONIALS?

Yes, I am very gratified that, like me, many others are getting good results with benfotiamine.  You may read the testimonials I have received to date at this link:  TESTIMONIALS.

Back To Top 

11.  WHERE CAN I BUY BENFOTIAMINE?

Please follow THIS LINK to be redirected to a website where you may order benfotiamine.

Back To Top 

Note:  If you have other questions you would like to see answered here, please email us at:  info@benfotiamine.org.

Back To Top

(Note:  Since benfotiamine is classified as a dietary supplement and not a drug, the U.S. FDA has not evaluated its effectiveness.  Benfotiamine therefore cannot be represented to diagnose, treat, cure or prevent any disease.  Also, the information above was assembled by a lay-person, not a medical professional nor practitioner.  For medical advice, please consult your health care professional.)


--
Dr Marwah

Saturday, July 18, 2009

General cancer information, including causes and screening ( www.cancerbackup.org.uk)


Cancerbackup merged with Macmillan Cancer Support in April 2008. It provide the same high quality, expertly developed information about cancer, and now it can make it available to everyone who needs it. The vision is for all people affected by cancer to have the information they want, when they want it - find out more on the main Macmillan website.
www.cancerbackup.org.uk/QAs/TreatmentsQAs/ChemotherapyQAs/All

News on Central Government Health Scheme in Indian Express 17 07 09

IN a bid to make the Central Government Health Scheme more accessible to Central Government employees, the Ministry of Health and Family Welfare is ready with a slew of measures to revamp the scheme. The Government has not only proposed that sample collection services for various tests be available at the doorsteps of the beneficiaries but that reports may also be viewed online. "Hindustan Lever Limited will provide sample collection services. Along with their card numbers, the beneficiaries will be given a password which will help them in viewing their reports online sitting at home," said Dr S Bhattacharjee, Additional Director, CGHS.
The ministry has also recently got the nod from the Cabinet to empanel any state of-the-art hospitals located outside the cities covered by CGHS. "The Ministry is soon going to float another tender to empanel more hospitals.
The last tender was floated in 2006. There are no specialized hospitals for diseases like cancer, which will be taken care of this time even if they are outside the CGHS cities," Health Secretary, Naresh Dayal told The Indian Express.
The Government is also planning to do away with the time-consuming "referral letter" system where the patient is required to obtain a referral letter from the Chief Medical Officer (CMO) before being able to avail of services at CGHS-empanelled hospitals.
The alarming rise in lifestyle diseases has prompted the Ministry into looking at introducing free prevention health check-ups for all the beneficiaries aged 40 years and above.
The dispensaries will also be equipped with dialysis units, ultrasound machines and X-ray machines. "We are entering into a Public Private Partnership (PPP) with Apollo hospitals which will provide instruments for dialysis. The dialysis will be done at as low a rate as Rs 1500," added Dr Bhattacharjee.
Moreover, since CGHS dispensaries are currently restricted to 25 cities, the Government has begun work on a health insurance scheme for Central Government employees after the Sixth Pay Commission recommendation last year. While, the Union Health ministry says that it is practically not possible to provide CGHS dispensaries in other cities, keeping in view the shortage of infrastructure, it has decided to make available the option of health insurance for government employees in non-CGHS areas. About 12 private companies have already sent their Expressions of Interest for the scheme.

Dietary Supplements YOUNG AGE TABLETS Idebenone, which is an analog of CoQ10

YOUNG AGE TABLETS Each film coated tablet contains :
Idebenone 45 mg
colour erythrosine lake


The next generation in anti-aging for the brain!

Idebenone, which is an analog of CoQ10, is a potent cerebral stimulant that can dramatically increase brain energy. Like CoQ10, Idebenone protects the heart and is a powerful antioxidant. Idebenone also enhances brain levels of serotonin, norepinephrine, and increases brain levels of nerve growth factor. Idebenone also protects the brain's myelin sheath and prevents damage to mitochondria. Idebenone has no known contraindications or side effects. Although less well known by the public, Idebenone is regarded as an important and protective anti-aging supplement.

Recommended dosage: one capsule, twice daily

These products are being offered as dietary supplements only and not as a substitute for medical care.

Friday, July 17, 2009

Central Government Health Scheme

Central Government Health Scheme
Some of the recent initiatives are listed below:

(1)Extension of CGHS: CGHS today covers 24 cities, apart from Delhi. Dehradun, Ranchi, Bhubaneshwar and Jammu are the cities where CGHS was extended during the last four years. (2) Computerization: To keep pace with the modern times, a massive computerisation work has been taken up under CGHS in collaboration with the National Informatics Centre. Computerization of the CGHS will result in lesser waiting period for beneficiaries at the dispensaries; on-line placement of indents on local chemists; availability of patient profiles; availability of medicines / drugs usage pattern, which will enable the CGHS to prepare a realistic list of formulary drugs; reduction in use of paper; removal of jurisdictional restriction (as regards the dispensary) for the beneficiaries, etc.

(3) Introduction of Plastic Cards: As part of the computerisation process, it has been decided to issue plastic cards individually to each beneficiary of the CGHS. This will enable beneficiaries to avail CGHS facility in any city should they happen to be in that city either on official work or on leave. Inter-city treatment will be possible after all cities are computerised and networked.

(4) Accreditation of labs with National Accreditation Board for Testing and Calibration Laboratories (NABL) : With a view to providing better quality treatment to CGHS beneficiaries, it was decided that only those private hospitals and diagnostic centres would be empanelled under the CGHS, as have been cleared by the Quality Council of India after it carried out inspection of the facilities available at these hospitals and diagnostic centres. It has also been decided that all the laboratories on the panel of CGHS have to get certificate issued by the NABL under the Quality Council of India.

(5) Medical Audit of Hospital Bills is an important exercise to assess the quality of services offered and expenditure incurred. In order to be sure that the bills raised by private empanelled hospitals are genuine and that the beneficiaries were required to undergo only that treatment as was required and that the hospital has not forced the beneficiary to undergo unnecessary tests / treatment at the hospital. The job of medical audit of Hospital bills has been outsourced to TPAs.

(6) Holding of Claims Adalats: Complaints were received in the CGHS and in the Ministry that old cases of reimbursement of medical expenses incurred by pensioners were pending for settlement for long time. It was decided that claims adalats be held in each Zonal office of CGHS, Delhi, under the chairmanship of the Additional Directors of the respective zones. Claims adalats were held annually, in each zone (East, Central, South and North Zones) in Delhi, during 2007 and 2008 and over 95% of the claims were settled in those adalats.

(7) Local Advisory Committees: Local Advisory Committee meetings are held in each CGHS dispensary on second Saturday of the month, which is attended by Area Welfare Officer appointed by the Chief Welfare Officer, Department of Personnel & Training, representatives from pensioners’ association, local chemist to resolve problems at dispensary level.

(8) Decentralisation and delegation of powers: Ministries / Departments have been delegated powers to handle all cases of reimbursement claims if no relaxation of rules was involved. Earlier they had powers to handle requests upto Rupees two lakhs and beyond that amount, the cases were referred to CGHS.

(9) Insulin: Orders have been issued to permit issue of Analogue (Insulin Vial/Cartridge) to CGHS beneficiaries and the extra cost would be borne by the CGHS. The beneficiaries would have to purchase the pen for utilization the analogue insulin.

(10) Outsourcing of cleaning process of dispensaries: As there were shortage of Class IV Staff in a large number of dispensaries in Delhi, it was decided to relocate Class IV staff from a few deficient dispensaries to other deficient dispensaries. To overcome the vacuum so created in some dispensaries, it was decided to outsource cleaning work for mechanised cleaning. The agency has been handling this work for the last five months, and the work done by them has been appreciated by all.

(11) Rate contract for purchase of drugs: It has been decided to run a pilot project under which dispensaries in Delhi will be permitted to place indents directly on the manufacturers on rate contract basis. If the proposal proves to be a success, then it may be extended to cover the entire CGHS. The benefit of this arrangement is that dispensaries / CGHS do not have to carry huge inventory of medicines and indents can be placed on a monthly basis depending on the need.

The Sixth Central Pay Commission recommended the introduction of health insurance scheme for Central Government employees and pensioners. It had recommended that for existing employees and pensioners, the scheme should be available on the voluntary basis, subject to their paying prescribed contribution. It has also recommended that the health insurance scheme should be compulsory for new Government employees who would be joining service after the introduction of the scheme. Similarly, it had recommended that new retirees, after the introduction of the insurance would be covered under the scheme.

An expression of interest has been floated by the Ministry of Health & Family Welfare inviting suggestions from insurance companies providing health insurance and health consultants on the structure, feasibility and viability of such a scheme.

This information was given by Shri Ghulam Nabi Azad, Union Minister for Health & Family Welfare in a written reply to a question in the Lok Sabha today. Source:PIB